Summary
Agilent Technologies, Inc.'s 2016 10-K filing reveals a company focused on life sciences, diagnostics, and applied chemical markets. The company generated $4.2 billion in net revenue for the fiscal year ended October 31, 2016, with 70% of that revenue coming from international markets. Agilent operates through three primary segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company is strategically investing in R&D and making targeted acquisitions to drive growth and expand its offerings in areas like cell analysis and core laboratory management. Despite a challenging economic environment and unfavorable currency movements impacting revenue by approximately 2%, Agilent demonstrated resilience with a 4% increase in net revenue year-over-year. Key growth drivers included the pharmaceutical and biotechnology markets, alongside solid performance in the food and environmental sectors. The company is committed to returning value to shareholders through dividends and share repurchases, and is focused on improving operating margins through operational efficiencies and strategic initiatives.
Financial Highlights
57 data points| Revenue | $4.20B |
| Cost of Revenue | $2.00B |
| Gross Profit | $2.20B |
| R&D Expenses | $329.00M |
| SG&A Expenses | $1.25B |
| Operating Expenses | $3.59B |
| Operating Income | $615.00M |
| Interest Expense | $72.00M |
| Net Income | $462.00M |
| EPS (Basic) | $1.42 |
| EPS (Diluted) | $1.40 |
| Shares Outstanding (Basic) | 326.00M |
| Shares Outstanding (Diluted) | 329.00M |
Key Highlights
- 1Agilent Technologies reported $4.2 billion in net revenue for fiscal year 2016, a 4% increase over the prior year.
- 2International markets accounted for a significant 70% of total net revenue.
- 3The company operates through three core segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
- 4Revenue growth was driven by strong performance in the pharmaceutical, biotechnology, food, and environmental markets.
- 5Agilent's R&D spending was $329 million in fiscal year 2016, underscoring its commitment to innovation.
- 6The company returned capital to shareholders through $150 million in cash dividends and significant share repurchases totaling $434 million in fiscal year 2016.
- 7Acquisitions of Seahorse Bioscience and iLab Solutions LLC in fiscal year 2016 aim to enhance Agilent's capabilities in cell metabolism and laboratory management.